RecruitingNot ApplicableNCT07009691

Hydrogen Water Intervention With Heart Rate Variability as an Outcome Biomarker in ME/CFS

Heart Rate Variability as an Autonomic Marker of Improvement in ME/CFS in a Hydrogen Water Treatment Study


Sponsor

Stony Brook University

Enrollment

50 participants

Start Date

Jun 9, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this clinical trial is to learn if the OTC supplement, hydrogen water, works to treat the fatigue-related symptoms and functional limitations in adults with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). It will also examine if heart rate variability (HRV) can be used to predict who will benefit from the hydrogen water treatment. The main questions it aims to answer are: Does the OTC supplement, hydrogen water, work to reduce the fatigue-related symptoms and improve functioning in participants who have ME/CFS? Can HRV be used to predict who will benefit from treatment with hydrogen water?


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Exclusion Criteria1

  • \-

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTHydrogen water which is prepared from an OTC supplement.

The intervention is hydrogen water which is prepared from an OTC supplement. It involves measurement of heart rate variability.


Locations(1)

Stony Brook University

Stony Brook, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07009691


Related Trials